These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 1884570)

  • 1. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
    Donnelly R; Macphee GJ
    Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects.
    Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
    J Clin Pharmacol; 1989 Jul; 29(7):635-42. PubMed ID: 2668352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
    Chrisp P; Goa KL
    Drugs; 1990 Feb; 39(2):234-63. PubMed ID: 2184002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of dilevalol on adrenoceptors.
    Louis WJ; Drummer OH; Tung LH
    J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S5-11. PubMed ID: 2464095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of dilevalol.
    Tenero DM; Bottorff MB; Given BD; Kramer WG; Affrime MB; Patrick JE; Lalonde RL
    Clin Pharmacol Ther; 1989 Dec; 46(6):648-56. PubMed ID: 2598569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol.
    Macphee GJ; Howie CA; Meredith PA; Elliott HL
    Br J Clin Pharmacol; 1991 Nov; 32(5):591-7. PubMed ID: 1954075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers.
    Kramer WG; Nagabhushan N; Affrime MB; Perentesis GP; Symchowicz S; Patrick JE
    J Clin Pharmacol; 1988 Jul; 28(7):644-8. PubMed ID: 3216030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of dilevalol (II). The pharmacokinetic, pharmacodynamic, and tolerance studies of dilevalol during repeated administration in healthy subjects.
    Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
    J Clin Pharmacol; 1989 Jul; 29(7):643-9. PubMed ID: 2760257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies.
    Neubeck M; Becker C; Henke D; Rösch W; Spahn-Langguth H; Mutschler E
    Arzneimittelforschung; 1993 Sep; 43(9):953-7. PubMed ID: 8240457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in lymphocyte beta-adrenoceptor density after dilevalol oral treatment.
    Sbirrazzuoli V; Drici M; Garraffo R; Candito M; Gibelin P; Morand P; Lapalus P
    Drugs Exp Clin Res; 1989; 15(5):223-9. PubMed ID: 2551622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effect of dilevalol is directly related to dose and plasma concentrations.
    Given BD; Perentesis G; Christopher JD; Herron J; Patrick JE; Kramer WG; Affrime MB
    Am J Cardiol; 1989 Jun; 63(19):12I-16I. PubMed ID: 2729123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of labetalol.
    McNeil JJ; Louis WJ
    Clin Pharmacokinet; 1984; 9(2):157-67. PubMed ID: 6370541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity.
    Wallin JD; Frishman WH
    J Clin Pharmacol; 1989 Dec; 29(12):1057-68. PubMed ID: 2693499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of age on the pharmacokinetics and antihypertensive responses to dilevalol.
    Elliott HL; Macphee GJ; Meredith PA
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():45-8. PubMed ID: 2370643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of beta 2-receptor stimulation in the peripheral vascular actions of the antihypertensive dilevalol.
    Watkins RW; Sybertz EJ; Cook J; Pula K; Cedeno K; Tedesco RP; McLeod R
    Arch Int Pharmacodyn Ther; 1989; 302():158-73. PubMed ID: 2576892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.
    Lalonde RL; Tenero DM; Kazierad DJ
    Pharmacotherapy; 1990; 10(1):15-28. PubMed ID: 2179899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion of dilevalol in breast milk.
    Radwanski E; Nagabhushan N; Affrime MB; Perentesis G; Symchowicz S; Patrick JE
    J Clin Pharmacol; 1988 May; 28(5):448-53. PubMed ID: 2899094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers.
    Kramer WG; Perentesis G; Affrime MB; Patrick JE
    Am J Cardiol; 1989 Jun; 63(19):7I-11I. PubMed ID: 2729127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism.
    Sybertz EJ; Watkins RW
    Am J Cardiol; 1989 Jun; 63(19):3I-6I. PubMed ID: 2567112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.